Merriman believes Novavax has a top technology in vaccine development for infectious diseases and set a $6-$8 price target on shares. :theflyonthewall.com
News For NVAX From The Last 14 Days
Check below for free stories on NVAX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
